Fenwick Represents Royalty Pharma in Acquisition of Synthetic Royalty Interest in Adstiladrin® from Ferring Pharmaceuticals Totaling up to $500 Million

Fenwick represented Royalty Pharma (Nasdaq: RPRX), a buyer of biopharmaceutical royalties and funder of innovation across the biopharmaceutical industry, in IP diligence regarding Royalty Pharma’s acquisition of a synthetic royalty on U.S. net sales of Ferring’s Adstiladrin® (nadofaragene firadenovec-vncg) for up to $500 million comprised of an upfront payment of $300 million and a $200 million manufacturing-related milestone payment.

Adstiladrin is a non-replicating adenovirus vector-based gene therapy for the treatment of adult patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Under the terms of the agreement, Royalty Pharma is acquiring a 5.1% percentage royalty on net sales of Adstiladrin in the United States, which will increase to 8.0% upon payment of the manufacturing-related milestone. The royalty is expected to end in the early to mid-2030s. More information can be obtained from Royalty Pharma’s announcement.

The Fenwick team included intellectual property partner Dr. Carl Morales, senior associate Dr. Glenn Foulds and associate Dr. Lucas Greder.


Don’t have an account yet?